



July 9, 2018

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Dear Sir/Madam,**

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of final USFDA approval for Hydroxychloroquine Sulfate Tablets USP, 200 mg, to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

  
**R. V. SATAM**  
**COMPANY SECRETARY**



Encl.: a.a.

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)

## **Lupin receives FDA approval for generic Hydroxychloroquine Sulfate Tablets USP, 200 mg**

**Mumbai, Baltimore, July 9, 2018:** Pharma major Lupin announced that it has received final approval for its Hydroxychloroquine Sulfate Tablets USP, 200 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.

Lupin's Hydroxychloroquine Sulfate Tablets USP, 200 mg is the generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg. It is indicated for:

- the treatment of uncomplicated malaria due to *P. falciparum*, *P. malariae*, *P. ovale*, and *P. vivax*
- the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported
- the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults
- the treatment of acute and chronic rheumatoid arthritis in adults

Hydroxychloroquine Sulfate Tablets USP, 200 mg had annual sales of approximately USD 215.3 million in the US (IQVIA MAT April 2018).

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 12<sup>th</sup> and 8<sup>th</sup> largest generics pharmaceutical company by market capitalization (31<sup>st</sup> March 2018, Bloomberg) and revenues (31<sup>st</sup> Mar 2018, Bloomberg LTM) respectively. The Company is the 4<sup>th</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (31st Mar 2018, Bloomberg LTM); 6<sup>th</sup> largest generic pharmaceutical player in Japan and 5<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – <http://www.twitter.com/lupinglobal>

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

